Today I'm continuing coverage on IMMX. Here's why.

SmallCapFirm

Nasdaq Profile (IMMX) Follow-Up Update For Thursday AM

February 3rd

SCF Readers,

Today I'm continuing coverage on IMMX. Here's why.

Over the last 3 weeks, the company has released several important news updates. Check them out:

#1.) 1/19 - ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

#2.) 1/25 - IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale

#3.) 1/31 - ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

With all these positive announcements, it may just be a matter of time until this under-the-radar Nasdaq profile starts generating some serious attention.

On top of that, IMMX may be building strong potential support.

After dropping to a low of $3.53 on 1/28/22, IMMX has since bounced back over the $4.00 level without falling below the $3.73 level in the past 3 days.

If potential support is building at that level, it may help create the building blocks for a continued bounce in the near term.

Since you've got a minute before today's opening bell, read my initial IMMX report below and get this Nasdaq profile on your radar quickly today.

-----

Nasdaq biopharma company Immix Biopharma, Inc. (IMMX) requires immediate attention.

ImmixBio™ is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases.

Their proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific™ Platform produces dr-ugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines.

The company's TME Normalization™ Technology allows their dr-ug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME.

They've uncovered fundamental biological systems that link oncology and immuno-dysregulated diseases. In addition to oncology, the company's pipeline includes Tissue-Specific Biologic™ candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

And right now, this Nasdaq profile has multiple potential catalysts that could lead it to a near term breakout.

Nasdaq Profile (IMMX) - 4 Potential Catalysts Lead The Way

No 1. - U.S. FDA Grants (RPD) Designation For IMX-110

No 2. - A Crazy Low Float

No 3. - Positive Results Thrill CEO

No 4. - IPO And Joining The NasdaqCM

But more on those in a second...

*IMMX's Insanely Huge Market Opportunities* (1)

STS is a rare cancer that begins in the tissues that connect, support, and surround the body structures. These tissues include muscle, fat, blood vessels, tendons, nerves and joint linings. The global STS market is estimated to reach approximately $6.5Bn by 2030 from the estimated $2.9Bn in 2019. Globally, there are roughly 116,000 new cases of STSs each year, of which 21,500 are in the European Union and 40,500 are in China. According to the American Cancer Society, there were roughly 13,000 new cases of STS in the United States during 2020. Approximately 160,000 people live with soft tissue cancers in the United States.

Colorectal cancers are cancers that arise from the colon, rectum and anus. The colorectal cancer market is estimated to reach approximately $31.2Bn by 2025 from the estimated $26.3Bn in 2019. According to the American Cancer Society, there were roughly 149,500 new cases of colorectal cancer in the United States. Globally, there are roughly 1,930,000 new cases of colorectal cancer each year, of which 519,500 are in Europe, 148,500 are in Japan, 20,500 are in Australia and New Zealand, and 555,000 are in China.

Inflammatory bowel disease is a complex disease with many contributing factors, primarily caused by an overactive immune system. Ulcerative colitis and Crohn’s disease are two of the most common forms of inflammatory bowel disease. The inflammatory bowel disease market is expected to reach $21.4Bn by 2024 from the existing $18.4Bn in 2019. Inflammatory bowel disease is estimated to affect over 2,000,000 people in the United States and over 5,000,000 people globally.

-----

IMMX Could Have New First-Line Therapy for STS

At the moment, current cancer treatment approaches are generally either cytotoxic chemotherapies or focus on targeting one single receptor or one single mutation, which limits their ability to counter an evolvable tumor and its micro-environment. (2)

With its Tissue-Specific Therapeutic IMX-110 treatment, the company believes it may have first-line therapy for STS and multiple other solid tumors, improving tolerability and progression free survival, while providing an alternative to conventional doxorubicin, a current first-line therapy initially approved for medical use in the United States in 1974. (1)

image

Given IMX-110’s novel feature of co-delivery of a resistance-suppressing poly-kinase inhibitor with an apoptosis inducer, the company believes IMX-110 can be used for treatment-resistant STS and other advanced, treatment-resistant cancers.

Plus, IMX-110 represents a dramatic shift away from a focus on cytotoxic or targeted therapies alone which, while producing initial tumor shrinkage, simultaneously activate pathways that lead to cancer relapse and treatment resistance.

image

Check out the full company presentation here.

-----

Right now, IMMX has several potential catalysts that could fuel this profile towards a vertical move near term. And none may be more important than this one...

IMMX No 1. Potential Catalyst - U.S. FDA Grants (RPD) Designation For IMX-110

U.S. Food and Dr-ug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

  • Rare Pediatric Disease Designation (“RPDD”) qualifies Immix Biopharma to receive fast track review, and a priority review voucher (“PRV”) at the time of marketing approval of IMX-110.
  • PRV holders can benefit from an expedited six-month review of a new dr-ug application for any disease by the FDA.
  • While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350Mn according to a January 2020 report on dr-ug development by the Government Accountability Office.

LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Dr-ug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial.

[...]

Read the full article here.

-----

IMMX No 2. Potential Catalyst - A Crazy Low Float

According to the Yahoo Finance website, IMMX has a tiny float.

The website reports this profile to have approximately 1.29Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts could help spark a vertical move in the short-term.

-----

IMMX No 3. Potential Catalyst - Positive Results Thrill CEO

ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

  • IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study
  • IMX-110 response rate surpassed standard of care doxorubicin’s response rate of 0% after 1 cycle of treatment in the same study
  • IMX-110 is in clinical development for STS, a $3Bn market expected to grow to $6.5Bn by 2030

LOS ANGELES, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced study data showing that ImmixBio’s lead candidate IMX-110 produced a 50% response rate in a first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mouse study, surpassing the STS standard of care doxorubicin’s 0% response rate in the same mouse study. The responses were assessed by RECIST 1.1 criteria applied to mice, with progression assessed after one cycle of treatment in a study funded by ImmixBio and conducted by a major STS oncology treatment center.

We strive to test our dr-ug candidates in the most realistic, challenging animal models available,” said Ilya Rachman, MD PhD, CEO of ImmixBio. “We are thrilled to see that in this first-line-therapy resistant STS model that IMX-110 showed significant activity. We believe this study is a preview of what our SMARxT Platform generating Tissue-Specific Therapeutics can do, a distinct alternative to the traditional ‘single target, single mutation’ development model.

[...]

Read the full article here.

-----

IMMX No 4. Potential Catalyst - IPO And Joining The NasdaqCM

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common st-ock at a public offering price of $5.00 per share, for gross proceeds of $21Mn, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common st-ock at the initial public offering price, less the underwriting discount, to cover over-allotments.

The shares began trading on the Nasdaq Capital Market on December 16, 2021 under the ticker symbol “IMMX.”

ThinkEquity acted as sole book-running manager for the offering.

The Company intends to use the net proceeds from the offering to fund a planned IMX-110 Phase 2a clinical trial in soft tissue sarcoma and IMX-110 + tislelizumab Phase 1b combination trial, for IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease), and for working capital and other general corporate purposes.

[...]

Read the full article here.

-----

IMMX Complete Recap - 4 Potential Catalysts Lead The Way

No 1. - U.S. FDA Grants (RPD) Designation For IMX-110

No 2. - A Crazy Low Float

No 3. - Positive Results Thrill CEO

No 4. - IPO And Joining The NasdaqCM

-----

Coverage is officially initiated on IMMX. When you have time later, do this:

image

Get IMMX on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1
Source 2


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SmallCapFirm and StockNewsWire LLC, SmallCapFirm has been hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. We have been paid fifteen thousand USD via bank wire transfer. We own zero shares of (IMMX). This fifteen thousand USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed. An owner of StockNewsWire LLC owns an interest in SmallCapFirm (SCF). Pursuant to an agreement between StockNewsWire LLC and Legends Media LLC, StockWireNews has been hired for a period beginning on 1/20/22 and ending on 1/21/22 to publicly disseminate information about (IMMX) via Website, Email and SMS. StockNewsWire LLC was paid eighty-two thousand five hundred USD via bank wire transfer. StockWireNews owns zero shares of (IMMX). This eighty-two thousand five hundred USD may be used for future marketing and advertising on this company or other companies on an ongoing basis. All companies will be disclosed.